Interventions to Manage Migraine

In the fourth video of the series, PA Christina Lindemann explores treatment strategies for managing migraine and improving patient outcomes. She reviews the goals of acute and preventive therapy, key factors that guide treatment selection, and the importance of tailoring care to each patient’s symptoms, needs, and response to therapy.

PA Lindemann also highlights the role of patient education, lifestyle support, and ongoing monitoring in comprehensive migraine care. With a focus on shared decision-making and practical management, this video helps PAs better support patients in preventing attacks, treating symptoms early, and improving quality of life.

Key Takeaways:

Both acute and preventive treatments have a place in comprehensive migraine care.
Patients should be guided to take acute medication at the first indication of a migraine attack.
Monitoring for treatment response and making appropriate adjustments is critical.

Previous Video Next Series

Speaker

Click on the photo below to learn more about the speaker.

Christina Lindemann, MSPAS, PA-C

References and Additional Resources:

Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039. https://pubmed.ncbi.nlm.nih.gov/34160823/

Lipton RB, Harriott AM, Ma JY, et al. Effect of ubrogepant on patient-reported outcomes when administered during the migraine prodrome: Results from the randomized PRODROME trial. Neurology. 2024;103(6):e209745. https://pubmed.ncbi.nlm.nih.gov/39197113/

Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;64(4):333-341. https://pubmed.ncbi.nlm.nih.gov/38466028/

Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6^TM) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357-367. https://pmc.ncbi.nlm.nih.gov/articles/PMC3057423/

Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41(9):854-861. https://pubmed.ncbi.nlm.nih.gov/11703471/

Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41-52. https://pubmed.ncbi.nlm.nih.gov/11098098/

Lipton RB, Kolodner K, Bigal ME, et al. Validity and reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia. 2009;29(7):751-759. https://pubmed.ncbi.nlm.nih.gov/19239676/

Supported by a grant from

Christina Lindemann, MSPAS, PA-C

Christina Lindemann is a board-certified physician associate specializing in neurology and headache medicine. She received her Bachelor of Science in neuroscience from the University of Minnesota in 2016 and Master of Science in Physician Assistant Studies from the University of Wisconsin – La Crosse – Gundersen – Mayo PA Program in 2019.

Following graduation from PA school, she built a clinical foundation for medical and procedural management of headache disorders working in neurology at Mayo Clinic. She later transitioned to the UC San Diego Health Headache Center in 2021, where she continues to treat patients with complex headache disorders, including migraine. She has an additional interest in education, authoring papers on headache disorders, presenting CME lectures on headache management, and precepting students.